AffiliationDivision of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK
MetadataShow full item record
AbstractDespite being the most frequent gain-of-function genetic alteration in human cancer, KRAS mutation has to date offered only limited potential as a prognostic and predictive biomarker. Results from the phase III SELECT-1 trial in non-small cell lung cancer (NSCLC) recently added to a number of historical and more contemporary disappointments in targeting KRAS mutant disease, including farnesyl transferase inhibition and synthetic lethality partners such as STK33. This narrative review uses the context of these previous failures to demonstrate how the knowledge gained from these experiences can be used as a platform for exciting advances in NSCLC on the horizon. It now seems clear that mutational subtype (most commonly G12C) of individual mutations is of greater relevance than the categorical evaluation of KRAS mutation presence or otherwise. A number of direct small molecules targeted to these subtypes are in development and have shown promising biological activity, with some in the late stages of preclinical validation.
CitationKRAS: reasons for optimism in lung cancer. 2018, 99: 20-27 Eur J Cancer
JournalEuropean Journal of Cancer
- Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
- Authors: Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA
- Issue date: 2010 Nov 1
- The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
- Authors: Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M
- Issue date: 2013 Jan-Feb
- KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition.
- Authors: Adderley H, Blackhall FH, Lindsay CR
- Issue date: 2019 Mar
- Current therapy of KRAS-mutant lung cancer.
- Authors: Ghimessy A, Radeczky P, Laszlo V, Hegedus B, Renyi-Vamos F, Fillinger J, Klepetko W, Lang C, Dome B, Megyesfalvi Z
- Issue date: 2020 Dec
- Dueling KRAS<sup>G12C</sup> Inhibitors Achieve Responses.
- Issue date: 2020 Jan